Key Companies: Depression - Leading Players Must Adapt to Remain Competitive

Aug 09, 2011, 04:39 ET from Reportlinker

NEW YORK, Aug. 9, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Key Companies: Depression - Leading players must adapt to remain competitive

http://www.reportlinker.com/p0591204/Key-Companies-Depression---Leading-players-must-adapt-to-remain-competitive.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Introduction

Companies seeking success in the depression market must react to the challenges posed by generic selective serotonin reuptake inhibitors (SSRIs). Complementing traditional antidepressants with novel modes of action in the adjunctive market will be an important point of entry, although demonstrating efficacy in patients with treatment-resistant depression is a sizable hurdle to overcome.

Features and benefits

* In-depth discussion of brand lifecycle and portfolio management strategies of key companies involved in the depression market.

* Assess trends in corporate strategies of companies active in the depression arena and understand the impact of key recent licensing deals.

* Identify the leading companies involved in depression and how their franchises have performed over 2002–10.

* Learn how companies can respond to future opportunities and challenges in the field.

Highlights

While GlaxoSmithKline is walking away from depression research, other companies are responding to the challenges posed by generic SSRIs by focusing on treatment-resistant patients. As physicians are willing to prescribe concomitant depression therapies, developers are trialing candidates to augment traditional antidepressants at second line.

Pfizer is ceding ground to rivals such as Forest and Eli Lilly, as generic venlafaxine takes hold and Pristiq underperforms. Pfizer's under-representation in the pipeline suggests that the company is moving away from depression research, rather than innovating and remaining at the forefront of the market.

Forest is a key player due to the company's marketing clout and ability to spot licensing opportunities. Its future presence should be sustained by ongoing deal-making activities. Lundbeck also sees growth potential in the depression market, evident by its commitment to the development of novel antidepressants in collaboration with Takeda.

Your key questions answered

* How successful are the portfolio management strategies most widely used in the depression market?

* How can emerging trends in the depression market be exploited by leading companies to guide strategic decisions?

* What can Pfizer's depression portfolio realistically achieve following Effexor's loss of market exclusivity?

* What are the implications of Forest's acquisition of Clinical Data to its outlook?

* How can Lundbeck ensure longevity in the depression market beyond the patent expiry of Cipralex?

Executive Summary

Strategic scoping and focus

Datamonitor key findings

OVERVIEW

Catalyst

Summary

COMPANY STRATEGIES

Strategic overview

Trends in corporate strategy

Targeting treatment-resistant depression with add-on therapies

Recent shifts in corporate strategy

Strategic refocusing at GlaxoSmithKline has resulted in a big player walking away from depression

Recent strategic partnerships/deals

Big Pharma seeks to partner with local players to expand geographical reach of mature brands

Forest's acquisition of Clinical Data was the only notable M&A activity

PFIZER

Corporate strategy

Pfizer leaps to the top spot in depression largely due to its takeover of Wyeth

Effexor franchise has reached the end of its lifecycle, although Pfizer is attempting to prolong market share with Pristiq

Pristiq will be unable to maintain Pfizer's antidepressant franchise revenues

Pfizer's pipeline suggests that the company is moving away from depression

Depression portfolio assessment

Mature brands define Pfizer's involvement in depression

SWOT analysis for Pfizer's depression portfolio

FOREST LABORATORIES

Corporate strategy

In-licensing from Lundbeck created Forest's antidepressant franchise

Acquisition of Clinical Data is a strong signal of Forest's intention to stay in the depression market

Further collaborations may widen Forest's future depression offerings

Depression portfolio assessment

Long-term future in depression ensured through in-licensing and acquisitions

SWOT analysis for Forest's depression portfolio

LUNDBECK

Corporate strategy

Antidepressant franchise has shaped Lundbeck's recent history

Lundbeck has been unable to match its commercial partner's success

Mixed results thus far from Lundbeck's collaboration with Takeda to develop a portfolio of novel antidepressant products

Depression portfolio assessment

High expectation rests with novel candidates to succeed Cipralex

SWOT analysis for Lundbeck's depression portfolio

PORTFOLIO REVIEW OF OTHER LEADING COMPANIES

AstraZeneca

Pipeline is targeted against the unmet needs in depression, building on Seroquel XR's initial success

Otsuka

Prolonging share of depression market with latest antipsychotic

Eli Lilly

Lilly maintains interest in the depression market

BIBLIOGRAPHY

Journal papers

Websites

Datamonitor reports

APPENDIX

PharmaVitae Explorer database

Contributing experts

Conferences attended

Report methodology

To order this report:

Pathology Industry: Key Companies: Depression - Leading players must adapt to remain competitive

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com